Mecolzine (Mesalazine)

Mesalazine acts locally on the colon lining by blocking cyclooxygenase and lipoxygenase enzymes, which lowers the production of prostaglandins and leukotrienes, key mediators of inflammation, thereby helping the intestinal mucosa heal.

The dosage of Mecolzine is determined by the prescribing clinician based on the severity of disease, patient weight, and response to therapy. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Mecolzine, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Mecolzine (mesalazine) is a locally acting aminosalicylate, whereas alternatives such as corticosteroids or biologics act systemically or target specific immune pathways. Mesalazine generally has a favorable safety profile for mild‑to‑moderate disease but may be less potent in severe cases.

Mecolzine should be stored at room temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight to maintain product stability and potency.

Mecolzine is supplied as a rectal formulation and is inserted into the rectum according to the prescriber's instructions, typically using a pre‑filled applicator or suppository, allowing direct delivery of mesalazine to the affected mucosa.

Serious risks include severe allergic reactions, significant gastrointestinal bleeding, liver enzyme elevations, pancreatitis, and rare cardiac inflammation. Patients should seek immediate medical attention if they experience symptoms such as rash, blood in stool, jaundice, severe abdominal pain, or chest discomfort.

Mecolzine is contraindicated in patients with known hypersensitivity to mesalazine or any component of the formulation, and it should be used with caution in individuals with severe renal or hepatic impairment, active infections, or those taking interacting medications without close monitoring.